Autolus Therapeutics plc: Blackstone Inc. amends Schedule 13D stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Blackstone Inc. amended its Schedule 13D filing on Autolus Therapeutics plc, disclosing a change to its beneficial ownership stake in the clinical-stage CAR-T developer. The filing, submitted under SEC accession number 0001193125-26-455574, updates Blackstone's previously reported position but did not specify a revised percentage in the headline disclosure. The amendment matters because Blackstone is a major institutional holder, and shifts in its stake can signal confidence or a rebalancing of exposure to Autolus's pipeline of cell therapies. Investors will watch for the full filing details to confirm the direction and size of the stake change, and for any subsequent 13D amendments that clarify Blackstone's intent.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13D's report. It can get details wrong, so check the source.
Named in this story
Blackstone Inc., Autolus Therapeutics plc